Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO

Revolution Medicines (NASDAQ: RVMD) 30-day option implied volatility is at 58; compared to its 52-week range of 40 to 125. Call put ratio 3.3 calls to 1 put after the company presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO.

You May Also Be Interested In

• Meta Platforms (META) Is Building A Cloud Business To Sell Excess Ai Compute - Bloomberg
• Kura Sushi USA Inc. (KRUS) PT Lowered to $70 at DA Davidson Ahead of Q3 Results
• DA Davidson Reiterates Buy Rating on Progress Software (PRGS) on Strong Q2 Results